Patents Assigned to Boehringer Ingelheim International GmbH
  • Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 11254688
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9
    Publication number: 20220042011
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to CARD9 pre-mRNA intron and exon sequences, which are capable of inhibiting the expression of CARD9 protein. Inhibition of CARD9 expression is beneficial for a range of medical disorders including inflammatory bowel disease, pancreatitis, IgA nephropathy, primary sclerosing cholangitis, cardiovascular disease, cancer and diabetes.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 10, 2022
    Applicants: Hoffmann-La Roche Inc., Boehringer Ingelheim International GmbH
    Inventors: Jay FINE, Mouhamadou Lamine MBOW, Joe Adam WAHLE, Fei SHEN, Elliott Sanford KLEIN, Kristina Mary SAI, Peter HAGEDORN, Anja MOELHART HOEG
  • Anti-CD40 antibodies
    Patent number: 11242394
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides
    Patent number: 11236072
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)-propanyl]- and N-[(Pyrazinylamino)¬propanyl]arylcarboxamide such as compound The present invention also relates to derivatives of such compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 1, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Radoslaw Lipinski, Stefan Scheuerer
  • Nebulizer and reservoir
    Patent number: 11229754
    Abstract: A nebulizer for nebulizing a fluid and a reservoir with a fluid are proposed. The reservoir includes a collapsible bag with the fluid, where the bag extends in a circumferential direction within the housing part and wherein the reservoir is manually rotated for tensioning the nebulizer.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: January 25, 2022
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joachim Carl Herbert Eicher, Alfred Von Schuckmann
  • Cell engineering using MICRORNAs
    Patent number: 11230725
    Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding the RNA, production host cell lines comprising the RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of the RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of the RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 25, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
  • Inhaler
    Patent number: 11224705
    Abstract: An inhaler for inhalation of a formulation in powder form includes: a magazine which is rotatable and contains pre-dosed doses of the formulation in capsules, a housing which is substantially round or disc-shaped, the housing having a housing part in which the rotatable magazine is disposed, where the housing part is fixedly coupled to the rotatable magazine, and is removable from the housing in order to facilitate replacement of the magazine by inserting a new magazine.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: January 18, 2022
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Holger Holakovsky, Jens Besseler, Jessica Frentzel-Beyme, Frank Herrmann
  • VSV CHIMERIC VECTORS
    Publication number: 20220010334
    Abstract: The present invention relates to VSV chimeric vectors, characterized in that the vectors comprise a gene coding for a glycoprotein GP of the Dandenong virus (DANDV) or Mopeia vims (MOPV) and lack a functional gene coding for envelope protein G of the VSV. The invention also provides VSV chimeric vector systems. In addition, the invention relates to uses of the VSV chimeric vectors and systems of the invention, including the use in medicine such as in the treatment of solid tumors.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 13, 2022
    Applicants: Vira Therapeutics GmbH, Boehringer Ingelheim International GmbH
    Inventors: Tobias NOLDEN, Patrik ERLMANN, Guido WOLLMANN, Zoltan BANKI, Bart SPIESSCHAERT, Janine KIMPEL, Dorothee VON LAER
  • Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors
    Patent number: 11213520
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 4, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Heribert Arnhof, Sebastian Carotta, Marco Hans Hofmann, Marc Kerenyi, Dirk Scharn
  • Drug delivery device
    Patent number: 11207474
    Abstract: A drug delivery device, in particular a nebulizer or inhaler, for dispensing a fluid includes a cartridge having a collapsible container within which the fluid is disposed, a mechanism to help the collapsing process and to prevent the collapsed container from expanding again, hence preventing the forming of vapor and gas bubbles within, where the mechanism is adapted to pressurize the fluid within the container during withdrawal of the fluid.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: December 28, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Stephen Terence Dunne
  • Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity
    Patent number: 11198696
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: December 14, 2021
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • Triazole benzamide derivatives as GPR142 agonists
    Patent number: 11179371
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, R4, n and m are as defined herein, which have valuable pharmacological properties, in particular bind to the GPR142 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as type 2 diabetes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 23, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Robert Augustin, Sebastian Bandholtz, Sara Frattini, Bernd Wellenzohn
  • Benzimidazole compounds and derivatives as EGFR inhibitors
    Patent number: 11174245
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dietrich Boese, Georg Dahmann, Harald Engelhardt, Mark Petronczki, Dirk Scharn
  • 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Bispecific binding molecules binding to VEGF and Ang2
    Patent number: 11161916
    Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11155539
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: October 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • ANTI-IL-23 ANTIBODIES
    Publication number: 20210317201
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 14, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Gerald Henry NABOZNY, Annette Bettina GALLER, Patrick GARIDEL, William Troy LOGING, Steven John PADULA, Torsten SCHULTZ-FADEMRECHT, Elaine Ee-Ling WANG
  • Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 11136337
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Viktor Vintonyak
  • Thienopyrimidones
    Patent number: 11136336
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: October 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Jens Willwacher
  • Substituted benzamides as RIPK2 inhibitors
    Patent number: 11130754
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 28, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pingrong Liu, Craig Andrew Miller, Maolin Yu, Zhonghua Zhang, Sabine Ruppel, Anil K. Padayana